Dexmedetomidine for awake craniotomy without laryngeal mask

Area of Science:

• Neurosurgery
• Anesthesiology
• Epileptology

Background:

• Awake craniotomy is crucial for speech area mapping in patients with brain lesions like cavernous angiomas.
• Dexmedetomidine is an alpha-2 adrenergic agonist with sedative and anxiolytic properties, potentially useful in awake surgeries.

Observation:

• Three epileptic patients with cavernous angiomas underwent awake surgery for speech area mapping.
• Dexmedetomidine was administered with varying loading and maintenance doses.
• Patients' consciousness levels were modulated without inducing agitation, hemodynamic instability, convulsions, or respiratory depression.

Findings:

• Dexmedetomidine successfully decreased patient consciousness, facilitating the awake craniotomy procedure.
• No adverse events such as hemodynamic instability, seizures, or respiratory compromise were observed.
• Patients tolerated the procedure well, and laryngeal mask airway was not required for ventilation.

Implications:

• Dexmedetomidine is a viable option for sedating patients during awake craniotomy, particularly for speech mapping.
• Its use may simplify anesthetic management by obviating the need for airway adjuncts like laryngeal masks.
• Further research can explore optimal dosing and patient selection for dexmedetomidine-assisted awake surgeries.